. A contraction in the pool of cardiovascular drugs under development has also been reported (10) Hwang et al. and Phase 2 models, indicating that the estimated hazard ratios (HRs) from these models should be interpreted as the average HR over time. 
small and medium-sized companies grew over time (Supplemental Figure 1) .
PROGRESS OF CARDIOVASCULAR DRUGS THROUGH
DEVELOPMENT. We found no evidence for a difference in probability of survival (defined as successful Hwang et al. STUDY LIMITATIONS. We used publicly available sources and commercial databases to identify the reasons for discontinuation, but additional factors may have played a role in these failures. However, we were able to identify the stated reasons for discontinuation of development for most (86%) of the drugs in our study cohort. In addition, although our study period was chosen to allow sufficient time for follow-up, it is possible that some of the discontinued drugs may be approved, and more trial results may be published in the future. akesselheim@partners.org. 3. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 Halted due to safety concerns (increased risk of death and cardiovascular events) *The inclusion criteria for the cariporide trial also included patients undergoing a high-risk percutaneous coronary intervention or coronary artery bypass surgery. †The primary outcome was the time to the first occurrence of a major cardiovascular event, a composite that included 4 components: death from coronary heart disease (defined as fatal MI excluding procedure-related events, fatal heart failure, sudden cardiac death, or other cardiac death), nonfatal MI (excluding procedure-related events), stroke, and hospitalization for unstable angina.
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MI ¼ myocardial infarction.
